Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomarkers, Tumor | 10 | 2019 | 522 | 0.850 |
Why?
|
| Adenocarcinoma | 7 | 2020 | 364 | 0.680 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2021 | 312 | 0.510 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2021 | 108 | 0.500 |
Why?
|
| ras Proteins | 3 | 2016 | 76 | 0.460 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2016 | 51 | 0.440 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2014 | 10 | 0.420 |
Why?
|
| DNA Mismatch Repair | 1 | 2014 | 35 | 0.410 |
Why?
|
| Immunohistochemistry | 10 | 2020 | 897 | 0.390 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 344 | 0.360 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2019 | 114 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 4 | 2019 | 347 | 0.350 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 439 | 0.340 |
Why?
|
| Kidney Neoplasms | 3 | 2019 | 174 | 0.340 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 1211 | 0.330 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 792 | 0.320 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 793 | 0.300 |
Why?
|
| Receptor, ErbB-4 | 2 | 2019 | 10 | 0.290 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2019 | 11 | 0.290 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2019 | 9 | 0.290 |
Why?
|
| Pancreatic Cyst | 2 | 2019 | 22 | 0.280 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2021 | 45 | 0.280 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2019 | 227 | 0.250 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2016 | 161 | 0.250 |
Why?
|
| Mutation | 5 | 2019 | 2658 | 0.220 |
Why?
|
| Cervix Uteri | 2 | 2020 | 58 | 0.180 |
Why?
|
| Celiac Disease | 1 | 2002 | 19 | 0.180 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 989 | 0.170 |
Why?
|
| Microscopy | 1 | 2022 | 100 | 0.170 |
Why?
|
| Cyst Fluid | 2 | 2019 | 5 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2018 | 31 | 0.170 |
Why?
|
| Lymph Nodes | 1 | 2002 | 231 | 0.170 |
Why?
|
| Aged | 14 | 2021 | 14834 | 0.170 |
Why?
|
| Urinary Bladder | 1 | 2021 | 48 | 0.170 |
Why?
|
| Urine | 1 | 2021 | 45 | 0.170 |
Why?
|
| Colposcopy | 1 | 2020 | 20 | 0.160 |
Why?
|
| Adenosarcoma | 1 | 2020 | 4 | 0.160 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 6 | 0.160 |
Why?
|
| Ampulla of Vater | 1 | 2020 | 12 | 0.160 |
Why?
|
| Female | 18 | 2021 | 33739 | 0.160 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2020 | 22 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 33 | 0.160 |
Why?
|
| Uterine Neoplasms | 1 | 2020 | 36 | 0.150 |
Why?
|
| Humans | 27 | 2022 | 64729 | 0.150 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 68 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 150 | 0.150 |
Why?
|
| Appendiceal Neoplasms | 1 | 2018 | 9 | 0.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2012 | 122 | 0.140 |
Why?
|
| Neoplasm Proteins | 2 | 2012 | 286 | 0.140 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 702 | 0.140 |
Why?
|
| Middle Aged | 13 | 2020 | 18106 | 0.140 |
Why?
|
| Sensitivity and Specificity | 6 | 2020 | 1159 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 62 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 5562 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 211 | 0.130 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 197 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2018 | 311 | 0.120 |
Why?
|
| Pancreas | 2 | 2019 | 154 | 0.120 |
Why?
|
| Histiocytosis | 1 | 2016 | 4 | 0.120 |
Why?
|
| Lipase | 1 | 2017 | 52 | 0.120 |
Why?
|
| Histiocytes | 1 | 2016 | 6 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 311 | 0.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2016 | 16 | 0.120 |
Why?
|
| Urothelium | 1 | 2016 | 22 | 0.120 |
Why?
|
| Lymphatic Vessels | 1 | 2016 | 32 | 0.120 |
Why?
|
| Adult | 10 | 2020 | 17230 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 491 | 0.120 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 77 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2015 | 21 | 0.110 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2022 | 66 | 0.110 |
Why?
|
| Hemangiosarcoma | 1 | 2015 | 24 | 0.110 |
Why?
|
| Fixatives | 1 | 2014 | 16 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 235 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2016 | 182 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 112 | 0.110 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2014 | 27 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2014 | 61 | 0.100 |
Why?
|
| Neoplasms, Fibroepithelial | 1 | 2014 | 3 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 39 | 0.100 |
Why?
|
| Pathology | 1 | 2013 | 12 | 0.100 |
Why?
|
| Male | 12 | 2021 | 30790 | 0.100 |
Why?
|
| Melanocytes | 1 | 2013 | 76 | 0.100 |
Why?
|
| Human papillomavirus 18 | 1 | 2011 | 4 | 0.090 |
Why?
|
| Human papillomavirus 16 | 1 | 2011 | 20 | 0.090 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2011 | 29 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 403 | 0.090 |
Why?
|
| Melanoma | 1 | 2013 | 332 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 133 | 0.080 |
Why?
|
| Prognosis | 3 | 2018 | 1770 | 0.070 |
Why?
|
| RNA-Binding Proteins | 2 | 2013 | 447 | 0.070 |
Why?
|
| Cytodiagnosis | 2 | 2022 | 46 | 0.070 |
Why?
|
| Flutamide | 1 | 2007 | 4 | 0.060 |
Why?
|
| Leuprolide | 1 | 2007 | 18 | 0.060 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2007 | 12 | 0.060 |
Why?
|
| Survival Rate | 2 | 2020 | 847 | 0.060 |
Why?
|
| Androgen Antagonists | 1 | 2007 | 32 | 0.060 |
Why?
|
| Mesentery | 1 | 2002 | 17 | 0.050 |
Why?
|
| Cytological Techniques | 1 | 2022 | 27 | 0.040 |
Why?
|
| Curettage | 1 | 2020 | 7 | 0.040 |
Why?
|
| Radiography | 1 | 2002 | 556 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2020 | 121 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2019 | 14 | 0.040 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2019 | 16 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 220 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 9 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 129 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 94 | 0.040 |
Why?
|
| beta Catenin | 1 | 2018 | 99 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 167 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 413 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2018 | 78 | 0.030 |
Why?
|
| Oncogenes | 1 | 2018 | 70 | 0.030 |
Why?
|
| Amylases | 1 | 2017 | 12 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2017 | 35 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 325 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 539 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 52 | 0.030 |
Why?
|
| Tetrasomy | 1 | 2016 | 3 | 0.030 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2016 | 16 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2016 | 54 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 26 | 0.030 |
Why?
|
| Young Adult | 2 | 2016 | 4771 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 512 | 0.030 |
Why?
|
| DNA | 1 | 2019 | 846 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 454 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 20 | 0.030 |
Why?
|
| Alcohols | 1 | 2014 | 12 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 33 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 41 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2014 | 46 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2015 | 81 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2483 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2014 | 127 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2013 | 19 | 0.030 |
Why?
|
| Breast | 1 | 2015 | 190 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 64 | 0.020 |
Why?
|
| Hybridomas | 1 | 2012 | 63 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2019 | 6803 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 3299 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 25 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 74 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1465 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 204 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 860 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 870 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1689 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 1104 | 0.020 |
Why?
|
| Pancreatitis, Chronic | 1 | 2008 | 21 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 875 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 285 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 282 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 84 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2007 | 103 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5758 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 6291 | 0.010 |
Why?
|
| Mice | 1 | 2012 | 11085 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 21292 | 0.010 |
Why?
|